{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:10:18Z","timestamp":1785463818931,"version":"3.56.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1937-4","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T10:02:45Z","timestamp":1562320965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Szumski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,5]]},"reference":[{"issue":"6","key":"1937_CR1","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1937_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/1756-185X.12754","volume":"18","author":"CS Lau","year":"2015","unstructured":"Lau CS, Chia F, Harrison A, Hsieh T-Y, Jain R, Jung SM, et al. APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis. 2015;18(7):685\u2013713.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"1937_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1\u201326.","journal-title":"Arthritis Rheumatol"},{"key":"1937_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3\u201315.","journal-title":"Ann Rheum Dis"},{"key":"1937_CR5","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/annrheumdis-2014-206047","volume":"74","author":"JAB van Nies","year":"2015","unstructured":"van Nies JAB, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AHM. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis. 2015;74:806\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1937_CR6","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1136\/annrheumdis-2012-201918","volume":"72","author":"C Barnabe","year":"2013","unstructured":"Barnabe C, Thanh NX, Ohinmaa A, Homik J, Barr SG, Martin L, et al. Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission. Ann Rheum Dis. 2013;72(10):1664\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1937_CR7","doi-asserted-by":"publisher","first-page":"R56","DOI":"10.1186\/ar4491","volume":"16","author":"Helga Radner","year":"2014","unstructured":"Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther. 2014;16(1):R56.","journal-title":"Arthritis Research & Therapy"},{"issue":"8","key":"1937_CR8","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1136\/annrheumdis-2016-209201","volume":"75","author":"G Schett","year":"2016","unstructured":"Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky DS, Naredo E, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016;75(8):1428\u201337.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1937_CR9","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.3899\/jrheum.141520","volume":"42","author":"TM Kuijper","year":"2015","unstructured":"Kuijper TM, Lamers-Karnebeek FBG, Jacobs JWG, Hazes JMW, Luime JJ. Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. J Rheumatol. 2015;42(11):2012\u201322.","journal-title":"J Rheumatol"},{"issue":"4 Suppl 78","key":"1937_CR10","first-page":"S22","volume":"31","author":"Y Tanaka","year":"2013","unstructured":"Tanaka Y, Hirata S, Saleem B, Emery P. Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2013;31(4 Suppl 78):S22\u2013S7.","journal-title":"Clin Exp Rheumatol"},{"key":"1937_CR11","first-page":"CD010455","volume":"9","author":"N van Herwaarden","year":"2014","unstructured":"van Herwaarden N, den Broeder AA, van der Maas A, Bijlsma JWJ, van Vollenhoven RF, van den Bemt BJF. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev. 2014;9:CD010455.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1937_CR12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/annrheumdis-2013-203302","volume":"73","author":"K Yoshida","year":"2014","unstructured":"Yoshida K, Sung Y-K, Kavanaugh A, Bae S-C, Weinblatt ME, Kishimoto M, et al. Biologic discontinuations studies: a systematic review of methods. Ann Rheum Dis. 2014;73(3):595\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1937_CR13","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/rheumatology\/kew464","volume":"56","author":"CJ Edwards","year":"2017","unstructured":"Edwards CJ, Fautrel B, Schulze-Koops H, Huizinga TWJ, Kruger K. Dosing down with biologic therapies: a systematic review and clinicians\u2019 perspective. Rheumatology (Oxford). 2017;56(11):1847\u201356.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1937_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/BOR.0b013e3283524e4c","volume":"24","author":"Y Tanaka","year":"2012","unstructured":"Tanaka Y. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol. 2012;24(3):319\u201326.","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"1937_CR15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/1756-185X.13238","volume":"21","author":"D-Y Chen","year":"2018","unstructured":"Chen D-Y, Lau CS, Elzorkany B, Hsu P-N, Praprotnik S, Vasilescu R, et al. Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature. Int J Rheum Dis. 2018;21(2):362\u201372.","journal-title":"Int J Rheum Dis"},{"issue":"11","key":"1937_CR16","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s00296-017-3780-8","volume":"37","author":"CS Lau","year":"2017","unstructured":"Lau CS, Gibofsky A, Damjanov N, Lula S, Marshall L, Jones H, et al. Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review. Rheumatol Int. 2017;37(11):1789\u201398.","journal-title":"Rheumatol Int"},{"issue":"9870","key":"1937_CR17","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","volume":"381","author":"JS Smolen","year":"2013","unstructured":"Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013;381(9870):918\u201329.","journal-title":"Lancet."},{"issue":"11","key":"1937_CR18","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1136\/annrheumdis-2011-200945","volume":"71","author":"A van der Maas","year":"2012","unstructured":"van der Maas A, Kievit W, van den Bemt BJF, van den Hoogen FHJ, van Riel PL, den Broeder AA. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis. 2012;71(11):1849\u201354.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1937_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/annrheumdis-2014-206696","volume":"75","author":"B Fautrel","year":"2016","unstructured":"Fautrel B, Pham T, Alfaiate T, Gandjbakhch F, Foltz V, Morel J, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: spacing of TNF-blocker injections in rheumatoid ArthritiS study). Ann Rheum Dis. 2016;75(1):59\u201367.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1937_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/annrheumdis-2014-206439","volume":"75","author":"J Haschka","year":"2016","unstructured":"Haschka J, Englbrecht M, Hueber AJ, Manger B, Kleyer A, Reiser M, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016;75(1):45\u201351.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1937_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1517\/14712598.2014.868433","volume":"14","author":"J Borr\u00e1s-Blasco","year":"2014","unstructured":"Borr\u00e1s-Blasco J, Gracia-P\u00e9rez A, Rosique-Robles JD, Caster\u00e1 ME, Abad FJ. Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients. Expert Opin Biol Ther. 2014;14(2):145\u201350.","journal-title":"Expert Opin Biol Ther"},{"key":"1937_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/1471-2474-14-299","volume":"14","author":"AA den Broeder","year":"2013","unstructured":"den Broeder AA, van Herwaarden N, van der Maas A, van den Hoogen FHJ, Bijlsma JW, van Vollenhoven RF, et al. Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskelet Disord. 2013;14:299.","journal-title":"BMC Musculoskelet Disord"},{"key":"1937_CR23","doi-asserted-by":"publisher","first-page":"h1389","DOI":"10.1136\/bmj.h1389","volume":"350","author":"N van Herwaarden","year":"2015","unstructured":"van Herwaarden N, van der Maas A, Minten MJM, van den Hoogen FHJ, Kievit W, van Vollenhoven RF, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ. 2015;350:h1389.","journal-title":"BMJ."},{"issue":"8","key":"1937_CR24","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1136\/annrheumdis-2013-203480","volume":"73","author":"X Mariette","year":"2014","unstructured":"Mariette X, Rouanet S, Sibilia J, Combe B, Le Lo\u00ebt X, Tebib J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014;73(8):1508\u201314.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1937_CR25","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/annrheumdis-2013-204632","volume":"74","author":"JS Smolen","year":"2015","unstructured":"Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis. 2015;74(5):843\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1937_CR26","doi-asserted-by":"publisher","first-page":"e019007","DOI":"10.1136\/bmjopen-2017-019007","volume":"8","author":"P Emery","year":"2018","unstructured":"Emery P, Burmester GR, Naredo E, Zhou Y, Hojnik M, Conaghan PG. Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the ImPact of residual inflammation detected via imaging TEchniques, drug levels and patient characteristics on the outcome of dose TaperIng of adalimumab in clinical remission rheumatoid ArThritis (RA) patients (PREDICTRA). BMJ Open. 2018;8(2):e019007.","journal-title":"BMJ Open"},{"issue":"1","key":"1937_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13075-017-1484-9","volume":"20","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Szumski A, Koenig AS, Jones TV, Marshall L. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. Arthritis Res Ther. 2018;20(1):8.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1937_CR28","doi-asserted-by":"publisher","first-page":"e000676","DOI":"10.1136\/rmdopen-2018-000676","volume":"4","author":"K Bechman","year":"2018","unstructured":"Bechman K, Sin FE, Ibrahim F, Norton S, Matcham F, Scott DL, et al. Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the optimizing TNF tapering in RA (OPTTIRA) trial. RMD Open. 2018;4(1):e000676.","journal-title":"RMD Open"},{"issue":"7","key":"1937_CR29","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/ard.2009.121491","volume":"69","author":"Y Tanaka","year":"2010","unstructured":"Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010;69(7):1286\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1937_CR30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/annrheumdis-2013-204016","volume":"74","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2015;74(2):389\u201395.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1937_CR31","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1136\/ard.2005.037333","volume":"64","author":"H Makinen","year":"2005","unstructured":"Makinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis. 2005;64(10):1410\u20133.","journal-title":"Ann Rheum Dis"},{"key":"1937_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13075-017-1346-5","volume":"19","author":"M Schoels","year":"2017","unstructured":"Schoels M, Alasti F, Smolen JS, Aletaha D. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition. Arthritis Res Ther. 2017;19:155.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"1937_CR33","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/art.39996","volume":"69","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Aletaha D, Gruben D, Zwillich SH, Krishnaswami S, Mebus C. Brief report: remission rates with Tofacitinib treatment in rheumatoid arthritis: a comparison of various remission criteria. Arthritis Rheumatol. 2017;69(4):728\u201334.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"1937_CR34","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1136\/annrheumdis-2016-209429","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Collaud Basset S, Boers M, Breedveld F, Edwards CJ, Kvien TK, et al. Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. Ann Rheum Dis. 2016;75(7):1268\u201371.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1937_CR35","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/annrheumdis-2013-204920","volume":"74","author":"R Fleischmann","year":"2015","unstructured":"Fleischmann R, van der Heijde D, Koenig AS, Pedersen R, Szumski A, Marshall L, et al. How much does disease activity score in 28 joints ESR and CRP calculations underestimate disease activity compared with the simplified disease activity index? Ann Rheum Dis. 2015;74(6):1132\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1937_CR36","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s00296-017-3749-7","volume":"37","author":"K Pavelka","year":"2017","unstructured":"Pavelka K, Akko\u00e7 N, Al-Maini M, Zerbini CAF, Karateev DE, Nasonov EL, et al. Maintenance of remission with combination etanercept\u2013DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access. Rheumatol Int. 2017;37(9):1469\u201379.","journal-title":"Rheumatol Int"},{"issue":"19","key":"1937_CR37","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1316133","volume":"371","author":"P Emery","year":"2014","unstructured":"Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin-Mola E, Buch MH, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med. 2014;371(19):1781\u201392.","journal-title":"N Engl J Med"},{"issue":"S11","key":"1937_CR38","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1002\/acr.20621","volume":"63","author":"JK Anderson","year":"2011","unstructured":"Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score Without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res. 2011;63(S11):S14\u201336.","journal-title":"Arthritis Care Res"},{"issue":"suppl 6","key":"1937_CR39","first-page":"vi16","volume":"51","author":"V. P. Bykerk","year":"2012","unstructured":"Bykerk VP, Massarotti EM. The new ACR\/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology. 2012;51(Suppl 6):vi16\u201320.","journal-title":"Rheumatology"},{"issue":"Suppl 85","key":"1937_CR40","first-page":"S75","volume":"32","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Aletaha D. Scores for all seasons: SDAI and CDAI. Clin Exp Rheumatol. 2014;32(Suppl 85):S75\u2013S9.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"1937_CR41","first-page":"1051","volume":"19","author":"T Pincus","year":"1992","unstructured":"Pincus T, Callahan L. Rheumatology function tests: grip strength, walking time, button test and questionnaires document and predict longterm morbidity and mortality in rheumatoid arthritis. J Rheumatol. 1992;19(7):1051\u20137.","journal-title":"J Rheumatol"},{"issue":"6","key":"1937_CR42","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3899\/jrheum.170586","volume":"45","author":"CRL Boot","year":"2018","unstructured":"Boot CRL, de Wind A, van Vilsteren M, van der Beek AJ, van Schaardenburg D, Anema JR. One-year predictors of presenteeism in workers with rheumatoid arthritis: disease-related factors and characteristics of general health and work. J Rheumatol. 2018;45(6):766\u201370.","journal-title":"J Rheumatol"},{"issue":"11","key":"1937_CR43","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1093\/rheumatology\/kes198","volume":"51","author":"C B\u00f6hler","year":"2012","unstructured":"B\u00f6hler C, Radner H, Ernst M, Binder A, Stamm T, Aletaha D, et al. Rheumatoid arthritis and falls: the influence of disease activity. Rheumatology. 2012;51(11):2051\u20137.","journal-title":"Rheumatology."},{"issue":"1","key":"1937_CR44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13075-015-0719-x","volume":"17","author":"H Radner","year":"2015","unstructured":"Radner H, Alasti F, Smolen JS, Aletaha D. Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. Arthritis Res Ther. 2015;17(1):203.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1937_CR45","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s00296-017-3833-z","volume":"37","author":"K Lee","year":"2017","unstructured":"Lee K, Choi S, Xu H, Kang J, Park D, Lee S. HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis. Rheumatol Int. 2017;37(12):2027\u201334.","journal-title":"Rheumatol Int"},{"issue":"12","key":"1937_CR46","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1002\/art.22190","volume":"54","author":"AK Brown","year":"2006","unstructured":"Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug\u2013induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006;54(12):3761\u201373.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1937_CR47","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/rheumatology\/kex080","volume":"56","author":"JM Hazes","year":"2017","unstructured":"Hazes JM, Luime JJ, Kuijper TM, van der Ven M, Weel AE, Gerards AH, et al. No clear association between ultrasound remission and health status in rheumatoid arthritis patients in clinical remission. Rheumatology. 2017;56(8):1276\u201381.","journal-title":"Rheumatology."},{"issue":"3","key":"1937_CR48","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/SMJ.0b013e318164e16a","volume":"101","author":"S Ozgocmen","year":"2008","unstructured":"Ozgocmen S, Ozdemir H, Kiris A, Bozgeyik Z, Ardicoglu O. Clinical evaluation and power Doppler sonography in rheumatoid arthritis: evidence for ongoing synovial inflammation in clinical remission. South Med J. 2008;101(3):240\u20135.","journal-title":"South Med J"},{"issue":"1","key":"1937_CR49","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/ard.2010.129924","volume":"70","author":"G Peluso","year":"2011","unstructured":"Peluso G, Michelutti A, Bosello S, Gremese E, Tolusso B, Ferraccioli G. Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. Ann Rheum Dis. 2011;70(1):172\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1937_CR50","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1002\/art.24596","volume":"60","author":"B Saleem","year":"2009","unstructured":"Saleem B, Brown AK, Keen H, Nizam S, Freeston J, Karim Z, et al. Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: a clinical and imaging comparative study. Arthritis Rheum. 2009;60(7):1915\u201322.","journal-title":"Arthritis Rheum"},{"key":"1937_CR51","first-page":"281","volume":"34","author":"Y Geng","year":"2016","unstructured":"Geng Y, Han J, Deng X, Zhang Z. Deep clinical remission: an optimised target in the management of rheumatoid arthritis? Experience from an ultrasonography study. Clin Exp Rheumatol. 2016;34:281\u20136.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1937-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1937-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1937-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T23:14:56Z","timestamp":1593818096000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1937-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,5]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1937"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1937-4","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,5]]},"assertion":[{"value":"29 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"These studies were conducted in accordance with the International Conference on Harmonization guidelines for Good Clinical Practice and the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all patients prior to enrollment. The institutional review board or independent ethics committee at each participating center reviewed and approved all consent forms and the study protocol.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YT has received speaking fees and\/or honoraria from Daiichi-Sankyo, Astellas, Eli Lilly, Chugai, Sanofi, AbbVie, Pfizer, YL Biologics, Bristol-Myers, GlaxoSmithKline, UCB, Mitsubishi-Tanabe, Novartis, Eisai, Takeda, Janssen, and Asahi-kasei and has received research grants from Mitsubishi-Tanabe, Bristol-Myers, Eisai, Chugai, Takeda, AbbVie, Astellas, Daiichi-Sankyo, Ono, MSD, and Taisho-Toyama. JSS has received research grant support from Abbott, BMS, MSD, Pfizer, Roche, and UCB and consultation and\/or speaking honoraria from Abbott, Astra-Zeneca, BMS, Celgene, Celltrion, Glaxo, Janssen, MSD, Pfizer, Roche, Samsung, Sanofi-Aventis, and UCB. HJ and LM were employees of Pfizer at the time the manuscript was written. AS is an employee of Syneos Health and was contracted by Pfizer to provide statistical support for the development of this paper. PE has received grant\/research support and consultancy fees from AbbVie, BMS, Lilly, MSD, Novartis, Pfizer, Roche, Samsung, Sandoz, and UCB.No nonfinancial competing interest exists for any author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}